Delivery Order SPE2DB24D2216-SPE2DB25FGPSQ
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,090.03 for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of April 25, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. The pharmaceutical will be...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $34,953.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injector pharmaceutical supply. The contract, executed on September 17, 2025, represents a non-competitive delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a $70,640.79 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion targeted for August 26, 2025. This competitively awarded, firm fixed-price contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $13,880.31 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of September 15, 2025. This non-competitive delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply agreement running through December 2026. The product will be performed at the...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $259,099.12 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of September 18, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution operations. ENBREL is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,543.12 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with an ultimate completion date of September 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a $68,437.63 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of June 3, 2025. This competitively awarded, firm fixed-price delivery order draws from AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceuticals...
- The Defense Logistics Agency awarded a $29,943.60 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, a biologic medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price, competitively awarded contract was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPSQDelivery Order
The Defense Logistics Agency awarded a $31,964.22 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement valued through December 2026. The product being delivered—ENBREL, a TNF inhibitor biologic used to treat rheumatoid arthritis and other autoimmune conditions—supports the military healthcare supply chain and Defense Health Agency requirements for specialty medications. As a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, AmerisourceBergen Drug Corp holds a significant position in federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive contract portfolio with DLA demonstrates its capability to fulfill diverse pharmaceutical needs ranging from specialty biologics to generic medications across multiple therapeutic domains. This delivery order reflects the company's ongoing role as a critical supplier of brand-name and generic pharmaceuticals, medical devices, and healthcare commodities to support military medicine and global defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.0k | 9/4/25 |